05:20 AM EST, 03/08/2024 (MT Newswires) -- Kyverna Therapeutics ( KYTX ) said late Thursday it has formed a collaboration with Stanford University to allow the use the of the company's KYV-101 investigational therapy for multiple sclerosis in a phase 1 investigator-initiated trial.

The trial will evaluate the safety, tolerability, and clinical activity of the drug in up to 12 patients and will be supported by correlative studies funded through a separate research collaboration between the company and Stanford, Kyverna said.